IBD:组织学评分与内镜评分对于溃疡性结肠炎临床复发的关系

2017-10-16 xuyihan MedSci原创

溃疡性结肠炎的治疗目标是取得临床和内镜下缓解,组织学治愈目前不是UC的治疗目标,本项研究探讨了内镜下缓解对于预测UC复发的可能性与时间的关系。

背景:溃疡性结肠炎的治疗目标是取得临床和内镜下缓解,组织学治愈目前不是UC的治疗目标,本项研究探讨了内镜下缓解对于预测UC复发的可能性与时间的关系。

方法:纳入2010年3月至2013年12月间进行结肠镜检查的获得临床缓解(部分梅奥评分<1)和内镜缓解(MSe <= 1)的患者60例,复发的定义为部分梅奥评分>=2,患者采取的治疗方案为药物,住院,或结肠切除。

结果:60例患者中 58.3%(n = 35)为女性,平均年龄52.7岁。 MSe = 1有38.3%(n = 23)组织学活动期有46.7%(n = 28), 19名患者出线临床复发,发生率累积风险分别为17.1%/ 24.5%/ 26.7%/ 40.1%(12/24/36/48个月)。 MSe = 1(P = 0.02)和组织学活性(P = 0.007)与复发显着相关。 其中只有组织学活性(P = 0.03)是复发的独立预测因子。

结论:组织学活动性评分处于活动期的患者是复发的高危人群,部分梅奥评分与复发无显着关系。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1926225, encodeId=878d1926225a7, content=<a href='/topic/show?id=9238e767680' target=_blank style='color:#2F92EE;'>#组织学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77676, encryptionId=9238e767680, topicName=组织学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Dec 14 20:18:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695001, encodeId=c5791695001e6, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Fri Nov 17 15:18:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261935, encodeId=6243126193549, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Oct 17 22:18:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263447, encodeId=cde7126344ec5, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue Oct 17 22:18:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253589, encodeId=049325358914, content=很好看.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/mzZkwf53jx0oribz8WkmVTPTSib4iaRMXz6nkEOaqWPjgyYWQoLa8J2WCicWvb8SrhhZz5sgUcwmQnMQ1lJcA7Fhxg/0, createdBy=9b182084756, createdName=yunger, createdTime=Tue Oct 17 06:46:34 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253584, encodeId=ec24253584ed, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Oct 17 06:44:52 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253362, encodeId=60f2253362e8, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon Oct 16 09:46:54 CST 2017, time=2017-10-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1926225, encodeId=878d1926225a7, content=<a href='/topic/show?id=9238e767680' target=_blank style='color:#2F92EE;'>#组织学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77676, encryptionId=9238e767680, topicName=组织学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Dec 14 20:18:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695001, encodeId=c5791695001e6, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Fri Nov 17 15:18:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261935, encodeId=6243126193549, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Oct 17 22:18:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263447, encodeId=cde7126344ec5, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue Oct 17 22:18:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253589, encodeId=049325358914, content=很好看.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/mzZkwf53jx0oribz8WkmVTPTSib4iaRMXz6nkEOaqWPjgyYWQoLa8J2WCicWvb8SrhhZz5sgUcwmQnMQ1lJcA7Fhxg/0, createdBy=9b182084756, createdName=yunger, createdTime=Tue Oct 17 06:46:34 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253584, encodeId=ec24253584ed, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Oct 17 06:44:52 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253362, encodeId=60f2253362e8, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon Oct 16 09:46:54 CST 2017, time=2017-10-16, status=1, ipAttribution=)]
    2017-11-17 nymo
  3. [GetPortalCommentsPageByObjectIdResponse(id=1926225, encodeId=878d1926225a7, content=<a href='/topic/show?id=9238e767680' target=_blank style='color:#2F92EE;'>#组织学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77676, encryptionId=9238e767680, topicName=组织学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Dec 14 20:18:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695001, encodeId=c5791695001e6, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Fri Nov 17 15:18:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261935, encodeId=6243126193549, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Oct 17 22:18:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263447, encodeId=cde7126344ec5, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue Oct 17 22:18:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253589, encodeId=049325358914, content=很好看.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/mzZkwf53jx0oribz8WkmVTPTSib4iaRMXz6nkEOaqWPjgyYWQoLa8J2WCicWvb8SrhhZz5sgUcwmQnMQ1lJcA7Fhxg/0, createdBy=9b182084756, createdName=yunger, createdTime=Tue Oct 17 06:46:34 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253584, encodeId=ec24253584ed, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Oct 17 06:44:52 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253362, encodeId=60f2253362e8, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon Oct 16 09:46:54 CST 2017, time=2017-10-16, status=1, ipAttribution=)]
    2017-10-17 docwu2019
  4. [GetPortalCommentsPageByObjectIdResponse(id=1926225, encodeId=878d1926225a7, content=<a href='/topic/show?id=9238e767680' target=_blank style='color:#2F92EE;'>#组织学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77676, encryptionId=9238e767680, topicName=组织学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Dec 14 20:18:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695001, encodeId=c5791695001e6, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Fri Nov 17 15:18:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261935, encodeId=6243126193549, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Oct 17 22:18:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263447, encodeId=cde7126344ec5, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue Oct 17 22:18:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253589, encodeId=049325358914, content=很好看.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/mzZkwf53jx0oribz8WkmVTPTSib4iaRMXz6nkEOaqWPjgyYWQoLa8J2WCicWvb8SrhhZz5sgUcwmQnMQ1lJcA7Fhxg/0, createdBy=9b182084756, createdName=yunger, createdTime=Tue Oct 17 06:46:34 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253584, encodeId=ec24253584ed, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Oct 17 06:44:52 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253362, encodeId=60f2253362e8, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon Oct 16 09:46:54 CST 2017, time=2017-10-16, status=1, ipAttribution=)]
    2017-10-17 bnurmamat
  5. [GetPortalCommentsPageByObjectIdResponse(id=1926225, encodeId=878d1926225a7, content=<a href='/topic/show?id=9238e767680' target=_blank style='color:#2F92EE;'>#组织学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77676, encryptionId=9238e767680, topicName=组织学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Dec 14 20:18:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695001, encodeId=c5791695001e6, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Fri Nov 17 15:18:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261935, encodeId=6243126193549, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Oct 17 22:18:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263447, encodeId=cde7126344ec5, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue Oct 17 22:18:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253589, encodeId=049325358914, content=很好看.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/mzZkwf53jx0oribz8WkmVTPTSib4iaRMXz6nkEOaqWPjgyYWQoLa8J2WCicWvb8SrhhZz5sgUcwmQnMQ1lJcA7Fhxg/0, createdBy=9b182084756, createdName=yunger, createdTime=Tue Oct 17 06:46:34 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253584, encodeId=ec24253584ed, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Oct 17 06:44:52 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253362, encodeId=60f2253362e8, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon Oct 16 09:46:54 CST 2017, time=2017-10-16, status=1, ipAttribution=)]
    2017-10-17 yunger

    很好看.学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1926225, encodeId=878d1926225a7, content=<a href='/topic/show?id=9238e767680' target=_blank style='color:#2F92EE;'>#组织学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77676, encryptionId=9238e767680, topicName=组织学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Dec 14 20:18:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695001, encodeId=c5791695001e6, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Fri Nov 17 15:18:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261935, encodeId=6243126193549, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Oct 17 22:18:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263447, encodeId=cde7126344ec5, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue Oct 17 22:18:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253589, encodeId=049325358914, content=很好看.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/mzZkwf53jx0oribz8WkmVTPTSib4iaRMXz6nkEOaqWPjgyYWQoLa8J2WCicWvb8SrhhZz5sgUcwmQnMQ1lJcA7Fhxg/0, createdBy=9b182084756, createdName=yunger, createdTime=Tue Oct 17 06:46:34 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253584, encodeId=ec24253584ed, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Oct 17 06:44:52 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253362, encodeId=60f2253362e8, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon Oct 16 09:46:54 CST 2017, time=2017-10-16, status=1, ipAttribution=)]
    2017-10-17 1dd8c52fm63(暂无匿称)

    了解了解.继续关注

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1926225, encodeId=878d1926225a7, content=<a href='/topic/show?id=9238e767680' target=_blank style='color:#2F92EE;'>#组织学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77676, encryptionId=9238e767680, topicName=组织学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Dec 14 20:18:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695001, encodeId=c5791695001e6, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Fri Nov 17 15:18:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261935, encodeId=6243126193549, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Oct 17 22:18:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263447, encodeId=cde7126344ec5, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue Oct 17 22:18:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253589, encodeId=049325358914, content=很好看.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/mzZkwf53jx0oribz8WkmVTPTSib4iaRMXz6nkEOaqWPjgyYWQoLa8J2WCicWvb8SrhhZz5sgUcwmQnMQ1lJcA7Fhxg/0, createdBy=9b182084756, createdName=yunger, createdTime=Tue Oct 17 06:46:34 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253584, encodeId=ec24253584ed, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Oct 17 06:44:52 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253362, encodeId=60f2253362e8, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon Oct 16 09:46:54 CST 2017, time=2017-10-16, status=1, ipAttribution=)]
    2017-10-16 Y—xianghai

    学习了新知识

    0

相关资讯

Measurement of disease activity in ulcerative colitis: Interobserver agreement a

Thia, K. T., E. V. Loftus, Jr., et al. (2011). "Measurement of disease activity in ulcerative colitis: Interobserver agreement and predictors of severity." Inflamm Bowel Dis 17(6): 1257-1264. BACKGRO

Inflamm bowel dis:溃疡性结肠炎患者早期结肠全切除风险的临床预测分析

溃疡性结肠炎患者中有一部分人群在确诊后数年后会进行结肠切除术,而哪些临床因素可以用来预测UC急性发作期住院的早期结肠癌切除的可能性呢?最近一项加拿大的基于人群的对照研究揭示了其中的秘密。

Inflamm bowel dis:miR-4728-3p通过调节信号通路抑制溃疡性结肠炎相关结肠直肠肿瘤

溃疡性结肠炎(UC)患者的肿瘤形成机制尚不清楚,最近有一项研究试图确定这一高危人群癌变发生的途径到底是怎么样的。

IBD:轻-中度溃疡性结肠炎中使用激素和生物制剂的注意事项

皮质类固醇相关的不良事件的发生风险可能会限制全身激素的使用。口服或者是局部使用第二代皮质类固醇和生物治疗是目前IBD有效的治疗方法。本篇文章进行了皮质类固醇和生物制剂对于溃疡性结肠炎的安全性和耐受性的分析。

INFLAMM BOWEL DIS:粘膜抗菌反应谱和粪便微生物成分与初次诊断为溃疡性结肠炎患者的病程关系

溃疡性结肠炎(UC)的疾病进程在不同个体之间存在很大差异,目前尚不能准确预测。之前已经有研究证实,肠道微生物群落与宿主的免疫应答是维持肠道稳态的关键因素,可能与疾病的最终结局相关。最近,瑞典的研究人员筛选了一群初次诊断为溃结且未经过治疗的患者,并对他们的肠道黏膜抗菌反应谱和粪便微生物组成进行研究,以期能得到与疾病发展进程相关的研究结果。参与实验的患者都是第一次被诊断为溃疡性结肠炎且未经过治疗的,疾

JCC:Vedolizumab 在治疗IBD中药物浓度与药物疗效的关系

之前已经有报道表明Vedolizumab的血清浓度与IBD患者的临床缓解率成正相关关系。近期有一份研究进一步报道了Vedolizumab在IBD治疗中诱导缓解的作用。